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SUMMARY
M4Eo acute myeloid leukaemia (AML) patients with the typical chromosome 16 abnormalities
have a favourable prognosis. These subtle 16q22 gene rearrangements can be difficult to detect
by conventional cytogenetic methods and if missed could lead to the incorrect assignment of
prognostic group and hence subsequent treatment strategies. We retrospectively studied 13
patients diagnosed with M4Eo AML for such chromosome 16 abnormalities comparing
conventionalcytogenetic(G-banding) andmolecular(FISH)methods.G-bandedanalysisdetected
only2patients withdefinitechromosome 16abnormalities whereasFISHdetected4patients,one
with thetypical inversion andthree with the typical chromosome 16translocation. FISHanalysis
also confirmed a false +ve G-banded result in one patient and a false -ve G-banded result in
anotherpatient. Finally,FISHconfirmed adeletion ofonechromosome 16homologuein another
patient indicating a poor prognosis. The overall survival of patients with the typical 16q22
rearrangements (n=4) was also significantly better (P=0.007) than patients with normal
chromosome 16 homologues or having other numerical and/or structural abnormalities (n=9).
ThissetofdatashowsthatFISHisamoreaccuratemethodforthedetectionofcryptic 16q22gene
rearrangements and because ofthe prognostic implications has become a mandatory test along
withconventional cytogenetics forall newlydiagnosed M4Eo AML patients in NorthernIreland.
INTRODUCTION
Reportshaveshownthatkaryotyping aleukaemic
cell population using conventional cytogenetic
methods is one ofthe most important prognostic
determinants in acute myeloid leukaemia
(AML).' 23 Both conventional cytogenetic and
molecular methods have led to the definition of
three prognostic groups (poor, intermediate &
favourable) in AML. Results from the Medical
ResearchCouncil (MRC) AML 10trial andother
international groups have clearly demonstrated
that AML patients with chromosome
abnormalities such as inv(16)/t(16;16), t(15;17)
andt(8;21)haveafavourableprognosis.4Patients
with an intermediate prognosis are those who
have acytogenetically normalkaryotype orother
chromosome abnormalities not associated with a
good or poor prognosis. Patients with a poor
prognosis are those with complex chromosome
abnormalities (i.e. numerical and structural) or
abnormalities such as abnormalities of
chromosomes 5 or 7.
The typical chromosome 16 rearrangements
consistingofeitheraninversion,inv(16)(pl3q22),
or a translocation, t(16;16)(p13;q22), are most
closelyassociatedwithadistinctsubtypeofacute
myelomonocyticleukaemiacharacterisedbybone
marrow eosinophilia. This subtype has been
assignedtheFAB-typeM4EoAMLsandalthough
theeosinophiliacanbevariableithasbeen shown
to be part of the leukaemia cell population.
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Molecular studies have shown that these
chromosome 16 abnormalities generate a fusion
protein(CBF13-MYHI1)betweenthecorebinding
factor (CBFf3) gene at 16q22 and the smooth
muscle myosin heavy chain (MYHi 1) gene at
16pl3 which plays a vital role in myeloid cell
transformationleadingtoleukaemia.Despitesuch
a transformation, it is still highly desirable to
detect those M4Eo AML patients who possess
such favourable chromosome 16 abnormalities.
Conventional cytogenetic methods consisting of
cell synchronisation and Giemsa banding (G-
banding)arecurrentlyusedtodetectchromosome
16 abnormalities but visualisation can often be
difficultespecially ifmetaphase preparations are
of a poor quality. It is therefore likely that the
frequency of these abnormalities is higher than
reported 6 and individual patients unknowingly
assigned to the wrong prognostic group and
subsequent treatment strategy. The need for a
more sensitive detection method as an adjunct to
conventional cytogenetics at diagnosis is
important for the correct stratification of such
AML patients.
In this retrospective study we have assessed a
molecular technique known as fluorescence in
situ hybridisation (FISH) using a dual colour
CBFB DNA probe for the detection of
chromosome 16 abnormalities and compared the
results with our own conventional cytogenetic
(G-banded) method and published data.
MATERIALS AND METHODS
Patients
Thirteen patients were diagnosed with M4Eo
AML in Northern Ireland at the Belfast City and
RoyalVictoriaHospitalsduringafiveyearperiod
(January 1995 toDecember 1999). Thediagnosis
and classification of patients were based on
standard morphologic, cytochemical and
immunophenotypic studies of leukaemic cells
accordingtocriteriaproposedbytheFAB andthe
MIC cooperative study groups.
Conventional cytogenetics (G-banding)
Chromosomes were prepared and analysed from
bone marrow aspirates using conventional
techniques. Routine cytogenetic analysis was
performed on all patients using a trypsin-giemsa
banding technique. Metaphase cells were
examinedfromshort-term(24hour)unstimulated
bone marrow cultures and chromosome
abnormalities were described according to ISCN
(I995).7Thenumberofmetaphasecells analysed
fully varied from 10 to 20 depending upon the
quality of individual cell preparations.
Fluorescence in situ hybridisation (FISH)
FISH was carried out using a commerically
available dual colour LSI CBFB3 16q22 probe
mixture (Vysis, UK) containing a red coloured
5'CBFf3 probe (R) positioned centromeric to the
16q22 breakpoint and a green coloured 3'CBFB
Fig 1. Representative fluorescence in situhybridisation
(FISH) analysis on metaphase spreads using the
LSI dual colour CBFB3 (16q22) probe mixture
(Vysis, UK). (A) Characteristic inversion 16 split
signal pattern consisting of a Red signal (R) at
16pll3 and a Green signal (G) at 16q22 on the
inverted chromosome 16. (B) Characteristic
chromosome 16 translocation split signal pattern
consisting of a fused Red/Green signal (R/G) at
16q22 and a Green signal (G) at 16p13 on one
chromosome 16 with aRedsignal (R) at 16q22 on
the other chromosome 16. (Published by
permission of Vysis UK).
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probe (G) positioned telomeric to the 16q22
breakpoint. Hybridisation to a normal
chromosome 16homologueshouldthereforeshow
afusedred/greensignal (R/G) atthe 16q22region
(Figla). Likewise,hybridisationtoachromosome
16 homologue containing an inv(16)(pl3q22)
will cause this fused R/G signal to split with the
individualred(R)andgreen(G) signals appearing
on opposite arms of the inv(16) chromosome
homologue (Fig la). Hybridisation to
chromosome 16homologuesinvolvedinat(16;16)
translocation preparation will result in a fused
red/green signal (R/G) on the q arm at 16q22 on
onechromosome 16homologueandagreensignal
(G) on the p arm at 16pl3 while the second
chromosome 16homologue will only containthe
red signal (R) on the q arm at 16q22 (Fig lb).
Statistical analysis
The outcome and survival of individual patients
fromthetimeofdiagnosiswasassessedinAugust
2001. Survival curves were estimated by the
Kaplan-MeiermethodandcomparedM4EoAML
patients that were +ve by FISH for the typical
16q22 gene rearrangements (n=4) and the
remaining M4Eo AMLpatients thatwere- veby
FISH for the typical 16q22 gene rearrangements
(n=9) using the log-rank test. A P value <0.05
was considered statistically significant. All
statistical computations were performed using
SPSS for Windows (version 10).
RESULTS
Patientandcytogenetic/FISHdataforthethirteen
M4Eo AMI, patients are presented in Table 1.
TABLE
Clinical data, cytogeneticfindings, FISH data and clinical outcime of13 patients diagnosed with
M4Eo AML in Northern Ireland.
Age WCCa Outcome*
Patient (yrs) (x109/l) Conventional Cytogeneties FISH (months)
definite 16q22 rearrangement
1 21 179 46,XX,inv(16)(pl3q22)[18a]/46,XX[2] +i Alive 32
2 43 ND 46,XY,inv(16)(pl3q22)[71/46,XX[13] +t Alive 80
suspected 16q22 rearrangement
3 81 144 46,XX,?inv(16)(pl3q22)[4]/46,XX[16] - Dead; <1
4 22 20 46,XX,?add(16)(?ql2)[151/46,XX[5] +t Alive 28
46,XY,del(16)(q22)[16a]/46,XY[4]
or
5 50 ND 46,XY,t(16;16)(pl3;q22)[16]/46,XY[4] +d Dead; <1
apparently normal cytogenetics
6 40 3 46,XX[O]q - Alive 50
7 52 170 46,XX[12]q - Dead; <1
8 59 120 46,XX[1O]q - Dead; 9
9 47 145 46,XY[20] - Dead; 4
other numerical/structural abnormalities
10 72 31 48,XY,+8,+22[cpl4] +t Alive 38
11 42 15 47,XY,+8[3]/46,XY[27] - Dead; 7
12 77 100 47,XY,+8,t(12;21)(pl3.3;qll)18]/46, XY[2] - Dead; <1
13 71 100 46,XY,del(18)(q21)[12] - Dead; 7
aWhite cell count; qqualified result (i.e. <20 cells analysed); iinv(16)(pl3q22), tt(16;16)(pl3;q22); ddel(16)(q22);
*Outcome in months from date ofdiagnosis; ND not determined.
C The Ulster Medical Society, 2003.
18Prognostic value ofFISH
Theirmedianageatdiagnosiswas50years (range
21-81 years) with a median white cell count
(WCC) of 100 x 109/1 (range 3 to 179 x 109/1).
Conventional cytogenetic and FISH studies
Conventional cytogenetic and FISH data for all
thirteen M4Eo AML patients are presented in
Table 1. Patients were grouped into 4 categories
according to conventional cytogenetic findings.
'Definite' 16q22 rearrangement
Conventional cytogenetics revealed 'definite'
16q22 rearrangements in two patients (patients 1
& 2) both of which were confirmed by FISH.
Furthermore, FISH was also able to further
characterise these abnormalities as the typical
chromosome 16 inversion in patient 1 and the
typicalchromosome 16translocationinpatient 2.
'Suspected' 16q22 rearrangement
Conventional cytogenetics indicated 'suspected'
16q22 rearrangements in three patients (patients
3- 5). However, FISH analysis excluded a 16q22
rearrangement in patient 3 (i.e. a false +ve G-
banded result) and confirmed the typical
chromosome 16 translocation in patient 4. FISH
also confirmed a deletion of one chromosome
homologue at 16q22 inpatient5 duetothelossof
the green telomeric CBF13 probe signal, the
prognosticsignificanceofwhichwillbediscussed
later.
'Apparently normal' cytogenetics
Conventionalcytogenetics wasapparentlynormal
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Fig 2. Kaplan-Meier survival curves for patients with
chromosome 16 rearrangements (n=4) vspatients
with either normal chromosome 16s or other
Chromosome abnormalities (n=9). Log-rank test
P=0.007.
for all autosomal chromosomes in 4 patients
(patients 6-9). However, a 'qualified' normal
result (i.e. <20 cells analysed) could only be
obtained in 3 of these patients (patients 6, 7, 8)
due to the overall yield and poor quality of
metaphasepreparations. FISH,however,wasable
to exclude any 16q22 gene rearrangement in all
four patients.
'Other numerical and/or structural' abnormalities
Conventional cytogenetics detected other
numerical and/or structural chromosome
abnormalities in four patients with 'apparently
normal' chromosome 16s (patients 10-13). FISH
excluded 16q22 rearrangements in three ofthese
patients (patients 11-13). FISH detected the
typical chromosome 16 translocation in patient
10 (i.e. a false -ve G-banded result) who was
reported tohave only atrisomy forchromosomes
8 and 22 by conventional cytogenetics, the
significance of which will be discussed later.
Survival of M4Eo AML patients
WecomparedthesurvivalofM4EoAMLpatients
with the typical chromosome 16 abnormalities
(n=4) and those patients with either normal
chromosome 16s or other chromosome
abnormalities (n=9) as illustrated in Figure 2.
This Kaplan-Meier survival curve clearly
demonstrated a significant longer survival and
hence better prognosis for M4Eo AML patients
with the typical chromosome 16 abnormalities
(log rank test X2 =7.27; P=0.007).
DISCUSSION
This small retrospective investigation of 13
patients with M4Eo AML has highlighted the
prognostic importance ofFISH notonly to detect
but also to confirm and/or exclude 16q22
rearrangements that have previously been
analysed using conventional cytogenetic
techniques.
Conventional G-banded analysis detected
'definite' chromosome 16 abnormalities in only
two (i.e. 15.4 %) ofthe 13 patients, bothofwhich
were confirmed by FISH. Because these 16q22
rearrangements can be difficult to detect, their
frequencies arelikely tobehigherthanreported 6
so it is of little surprise that FISH was able to
detect a further two patients with the typical
chromosome 16 abnormalities in our group of
patients. FISH not only highlighted a false +ve
G-bandedresultin onepatientwhoonly survived
one month but also highlighted a false -ve G-
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Fig 3. G-banded metaphase spreads in individual M4Eo
AML patients. (a) Metaphase spread giving a
false -ve G-banded result (patient 10) with
'apparently normal' chromosome 16s but
trisomiesforchromosome 8and22. (B)Metaphase
spreadfor apatientdiagnosedinMay 2002clearly
showing the typical chromosome 16 inversion
[inv(16)].
banded result in anotherpatient who wasthought
to be carrying only trisomies for chromosomes 8
and 22 (Fig. 3a). FISH clearly unmasked the
typicalchromosome 16translocationabnormality
in this patient who is still alive after 38 months.
Although trisomy 22 itselfis rare in AML, it is a
common secondary chromosome abnormality in
patients with 16q22 rearrangements, as are
deletions of the long arm of chromosome 7 and
trisomy8.5 8Interestingly, othergroupshavealso
unmasked cryptic chromosome 16 abnormalities
uponreexaminationofseveralAMLsthatinitially
hadbeenclassifiedashavingtrisomy 8ortrisomy
22 as the only cytogenetic abnormality.9 The
detection offalse G-bandedresults, both +ve and
-ve, using the FISH technique clearly
demonstrates that, without FISH, patients can be
assigned to the wrong prognostic groups and
hence treatment stratification.
FISH confirmed a deletion with a breakpoint at
16q22 in apatient 'suspected' ofhaving a 16q22
rearrangement by conventional cytogenetics. It
has been shown thatpatients with such adeletion
have a poorer prognostic outcome than patients
with the typical 16q22 rearrangements.10 At the
molecularlevel, thesepatients are also morethan
likely to have different consequences, since
without the involvement of the smooth muscle
myosin heavy chain gene located at 16p113, the
generationofthetypicalchimericCBFB-MYH 1I
fusion gene is not expected. It has also been
suggested that patients with the deleted
chromosome 16 abnormality shouldbe excluded
from the current treatment recommendations
reserved for patients with the typical 16q22
rearrangment.'0 The survival of our patient with
the 16q22 deletion (i.e. < 1 month) is concordant
with the survival and poorer outcome reported
for similar patients in other studies.10-'2
Overall, the four patients with typical 16q22
rearrangements have had a better prognostic
outcome compared to the other nine patients.
Only one of these nine patients was still alive at
the time of assessment, the other eight having
alreadydiedwithamediansurvivalof2.5 months
(range 1-9 months).
Two newly diagnosed M4Eo AMLpatients have
beenreferredforcytogeneticinvestigations since
the introduction of mandatory FISH screening
for 16q22 rearrangements. The first patient,
diagnosedinDecember2001, showedthetypical
inversionbyconventionalcytogeneticsandwhich
was confirmed by FISH. The second patient,
diagnosed in May 2002 also showed the typical
inversionbyconventionalcytogenetics. Thebone
marrow sample for this second patient yielded
metaphasespreadsofextremelygoodqualityand
therefore the inversion was easily confirmed by
conventional cytogenetics (Fig. 3b). FISH
analysis, however, was still carried out and
confirmedtheconventionalcytogeneticfindings.
The Ulster Medical Society, 2003.
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Although this series of patients is small it was
notable that 50% of the chromosome 16
abnormalities detected showed the chromosome
16 translocation. This is in contrast to some
previous studies that showed a higher incidence
ofchromosome 16 inversions.'2Whetherthis is a
mere chance finding, a feature of the local
populationorreflectsfailureofotherlaboratories
tocharacterisethechromosome 16translocations
is unclear.
In conclusion, FISH has proved to be a more
sensitive technique compared to conventional
cytogenetics for the detection of 16q22
rearrangements. Because ofthe simplicity ofthis
techniqueandtheavailabilityofthecommercially
available CBFB3 probe, FISH has now become a
mandatorydiagnostictestalongsideconventional
cytogenetics for detection of 16q22
rearrangements in newly diagnosed M4Eo AML
patients in Northern Ireland.
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